Amoxicillin

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.1. Access group antibiotics

EMLc | Codes ATC: J01CA04

Indication	Acute otitis media Code ICD11: AB00
INN	Amoxicillin
Type de médicament	Chemical agent
Groupes d'antibiotiques	A ACCESS
Type de liste	Liste de base
Formulations	**Oral > Liquid:** 125 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc) ; 250 mg per 5 mL (as trihydrate) powder for oral liquid (EMLc) **Parenteral > General injections > unspecified:** 250 mg in vial (as sodium) powder for injection ; 500 mg in vial (as sodium) powder for injection ; 1 g in vial (as sodium) powder for injection **Oral > Solid > dispersible tablet:** 250 mg (scored) (as trihydrate) (EMLc) ; 500 mg (scored) (as trihydrate) (EMLc) **Oral > Solid > dosage form:** 250 mg (as trihydrate) ; 500 mg (as trihydrate)
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2023 (TRS 1049)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Wikipédia	Amoxicillin
DrugBank	Amoxicillin

Recommandation du comité d'experts

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.

Recommandations de la LME : Acute otitis media

Premier choix	Second choix
amoxicillin	amoxicillin + clavulanic acid

